Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 4, 1999, Pages 589-598

  Dragovich, Peter S ^a   Zhou, Ru ^a   Skalitzky, Donald J ^a   Fuhrman, Shella A ^a   Patick, Amy K ^a   Ford, Clifford E ^a   Meador III, James W ^a   Worland, Stephen T ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

Cysteine; Inhibitor; Irreversible; Protease; Rhinovirus

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; TRIPEPTIDE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS;

AMIDES; CYSTEINE ENDOPEPTIDASES; HELA CELLS; HUMANS; KINETICS; PEPTIDES; PROTEASE INHIBITORS; VIRAL PROTEINS;

HUMAN RHINOVIRUS 3; HUMAN RHINOVIRUS SP.; RHINOVIRUS;

EID: 0032987794     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00005-X     Document Type: Conference Paper

References (31)

1. (a) Couch, R. B. Rhinoviruses. In Virology, 2nd Ed.; Fields, B. N.; Knipe, D. M., Eds.; Raven Press: New York, 1990; Vol. 1, Chapter 22, pp 607-629.
2. (b) McKinlay, M. A.; Pevear, D. C.; Rossmann, M. G. Annu. Rev. Microbiol. 1992, 46, 635.
3. (c) Phillpotts, R. J.; Tyrrell, D. A. J. Br. Med. Bull. 1985, 41, 386.
4. (d) Gwaltney, J. M. In Principles and Practices of Infectious Diseases; Mandell, G. L., Douglas, R. G., Bennett, J. E., Eds.; John Wiley & Sons: New York, 1985, Chapter 38, pp 351-355.
5. (e) Gwaltney, J. M. In Viral Infections of Humans; Evans, A. S., Ed.; Plenum Publishing Corp.: New York, 1982; Chapter 20, pp 491-517.
6. (a) Rueckert, R. R. In Virology, 2nd Ed.; Fields, B. N., Knipe, D. M., Eds.; Raven Press: New York, 1990; Vol. 1, Chapter 20, pp 507-548.
7. (b) Kräusslich, H.-G.; Wimmer, E. Annu. Rev. Biochem. 1988, 57, 701.
8. (a) Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Reich, S. R.; Prins, T. J.; Marakovits, J. T.; Littlefield, E. S.; Zhou, R.; Tikhe, J.; Ford, C. E.; Wallace, M. B.; Meador, III J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Harr, J. E. V.; DeLisle, D. M.; Worland, S. T. J. Med. Chem. 1998, 41, 2806.
9. (b) Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Reich, S. H.; Marakovits, J. T.; Prins, T. J.; Zhou, R.; Tikhe, J.; Littlefield, E. S.; Bleckman, T. M.; Wallace, M. B.; Little, T. L.; Ford, C. E.; Meador, III, J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; DeLisle, D. M.; Worland, S. T. J. Med. Chem. 1998, 41, 2819.
10. (a) Cordingley, M. G.; Callahan, P. L.; Sardana, V. V.; Garsky, V. M.; Colonno, R. J. J. Biol. Chem. 1990, 265, 9062.
11. (b) Orr, D. C.; Long, A. C.; Kay, J.; Dunn, B. M.; Cameron, J. M. J. Gen. Virol. 1989, 70, 2931.
12. (c) Cordingley, M. G.; Register, R. B.; Callahan, P. L.; Garsky, V. M.; Colonno, R. J. J. Virol. 1989, 63, 5037.
13. 2′, etc.) is described in: Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157.
14. The optimization of a series of peptidyl thrombin inhibitors utilizing a similar approach was recently described. See: Brady, S. F.; Stauffer, K. J.; Lumma, W. C.; Smith, G. M.; Ramjit, H. G.; Lewis, S. D.; Lucas, B. J.; Gardell, S. J.; Lyle, E. A.; Appleby, S. D.; Cook, J. J.; Holahan, M. A.; Stranieri, M. T.; Lynch, Jr., J. J.; Lin, J. H.; Chen, I.-W.; Vastag, K.; Naylor-Olsen, A. M.; Vacca, J. P. J. Med. Chem. 1998, 41, 401.
15. (a) Geysen, H. M.; Meloen, R. H.; Barteling, S. J. Proc. Natl. Acad. Sci. USA 1984, 81, 3998.
16. (b) Valerio, R. M.; Bray, A. M.; Maeji, N. J. Int. J. Peptide Protein Res. 1994, 44, 158.
17. Coste, J.; Le-Nguyen, D.; Castro, B. Tetrahedron Lett. 1990, 31, 205.
18. Rink, H. Tetrahedron Lett. 1987, 28, 3787.
19. Wade, J. D.; Bedford, J.; Sheppard, R. C.; Tregear, G. W. Peptide Res. 1991, 4, 194.
20. (a) Carpino, L. A. J. Am. Chem. Soc. 1993, 115, 4397.
21. (b) Carpino, L. A.; El-Faham, A.; Albericio, F. Tetrahedron Lett. 1994, 35, 2279.
22. Available Chemicals Directory, v97.1, Molecular Design Limited, 14600 Catalina Street, San Leandro, CA 94577.
23. Previous structure-activity studies demonstrated that a variety of N-terminal moieties were tolerated in the tripeptide 3CP inhibitor design. See ref. 3b above.
24. Wells containing compounds 8a-g displayed inhibition values ranging from 85% to 97% when tested in the high throughput 3CP enzyme assay system.
25. A high-throughput antiviral assay was also utilized to examine compounds 8 prepared on solid phase. However, such examination did not reveal any molecules worthy of solution-phase resynthesis other than those identified by the anti-3CP assay.
26. The incorporation of additional N-terminal carboxamides derived from aromatic heterocyles into tripeptidyl 3CP inhibitors is ongoing.
27. Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
28. Webber, S. E.; Tikhe J.; Worland, S. T.; Fuhrman, S. A.; Hendrickson, T. F.; Matthews, D. A.; Love, R. A.; Patick, A. K.; Meador, III J. W.; Ferre, R. A.; Brown, E. L.; DeLisle, D. M.; Ford, C. E.; Binford, S. L. J. Med. Chem. 1996, 39, 5072.
29. Leatherbarrow, R. J. ENZFITTER, Biosoft, Ferguson, MO 63135.
30. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. J. Natl. Cancer Inst. 1989, 81, 577.
31. Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Van Eemeren, K.; Stokbroekx, R.; Janssen, P. A. J. Antimicrob. Agents Chemother. 1992, 36, 100.